OncoMatch/Clinical Trials/NCT05020444
TriPRIL CAR T Cells in Multiple Myeloma
Is NCT05020444 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including TriPRIL CAR T Cells and Cyclophosphamide for multiple myeloma.
Treatment: TriPRIL CAR T Cells · Cyclophosphamide · Fludarabine — This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Must have received: IMiD
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Must have received: anti-CD38 antibody
at least 3 prior regimens of systemic therapy including proteasome inhibitor, IMiDs and anti-CD38 antibody; or has "triple-refractory" disease following treatment with proteasome inhibitor, IMiD and anti-CD38 antibody
Cannot have received: systemic therapy
Any prior systemic treatment for multiple myeloma within the 14 days prior to scheduled leukapheresis unless discussed with the medical monitor
Cannot have received: systemic steroid therapy
Exception: ≤10 mg prednisone or equivalent allowed
Receiving high-dose (e.g., >10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Cannot have received: immunosuppressive therapy
any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Cannot have received: autologous stem cell transplantation
Autologous stem cell transplantation within 3 months prior to leukapheresis
Cannot have received: allogeneic stem cell transplantation
Any prior allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy
Other CAR-T cell therapy within 6 months of leukapheresis
Cannot have received: bispecific T cell engager
No Bispecific T cell engagers within 6 months of apheresis
Cannot have received: (bendamustine)
No bendamustine within 6 months of apheresis
Lab requirements
Blood counts
ANC ≥1.0k/μl, PLT ≥50k/μl (no platelet transfusion within 7 days; no neupogen within 7 days, neulasta within 14 days)
Kidney function
Creatinine clearance ≥30 mL/min and not on dialysis
Liver function
AST/ALT <3 x ULN; Direct bilirubin <1.5 x ULN (allow x 3 ULN for Gilbert's syndrome)
Cardiac function
LVEF ≥40% by ECHO or MUGA scan
Adequate organ and marrow function as defined below: O2 saturation ≥92% on room air while awake; LVEF ≥40% by ECHO or MUGA scan; ANC ≥1.0k/μl, PLT ≥50k/μl, (NOTE: Platelet transfusion not allowed within 7 days; growth factor neupogen not allowed within 7 days, neulasta within 14 days); Creatinine clearance ≥30 mL/min and not on dialysis; AST/ALT <3 x ULN; Direct bilirubin <1.5 x ULN (allow x 3 ULN for Gilbert's syndrome); PTT, PT/INR <1.5 x ULN, unless on a stable dose of anti-coagulant for a thromboembolic event
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05020444 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy, systemic steroid therapy, immunosuppressive therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages